Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Wolters Kluwer and OpenAI expand AI partnership to enhance trusted Expert AI for regulated professionals.

Market News
03 Jun 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Wolters Kluwer has expanded its enterprise AI collaboration with OpenAI to develop advanced Expert AI solutions for professionals in regulated fields like healthcare, law, and accounting. This partnership integrates OpenAI's latest AI capabilities with Wolters Kluwer's domain expertise and governance principles to improve decision-making and productivity in high-stakes environments. Key applications include enhanced clinical decision support in healthcare and automated workflows in tax and accounting, with growing adoption among U.S. customers. The collaboration aims to deliver trusted, efficient AI tools that maintain accuracy and compliance across professional sectors.

More News

NRx Pharmaceuticals shares drop 19% after announcing a public stock offering.

NRx Pharmaceuticals shares drop 19% after announcing a public stock offering.

NRx Pharmaceuticals' stock fell 19.05% in after-hours trading following the announcement of a proposed underwritten public offering of common stock. The company plans to use the proceeds for working capital and general corporate purposes to support g...

Company Fundamentals
Bearish
26 minutes ago
Sigenergy launches SigenAgent AI to optimize solar, storage, and EV charging globally via app upgrade.

Sigenergy launches SigenAgent AI to optimize solar, storage, and EV charging globally via app upgrade.

Sigenergy has introduced SigenAgent, an AI-driven energy management system designed to optimize solar power, energy storage, and electric vehicle charging. Available globally through the mySigen App 4.0 as a software upgrade, SigenAgent allows users ...

Others
Bullish
1 hour ago
Nipocalimab shows sustained reduction in lupus disease activity in Phase 2 study, advancing to Phase 3 trials.

Nipocalimab shows sustained reduction in lupus disease activity in Phase 2 study, advancing to Phase 3 trials.

Johnson & Johnson's investigational drug nipocalimab significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) during a Phase 2 study, with effects sustained through 52 weeks. The drug targets pathoge...

Company Fundamentals
Bullish
2 hours ago
SpaceX plans $75B IPO by selling 555.6M shares at $135 each, aiming for one of the largest public offerings.

SpaceX plans $75B IPO by selling 555.6M shares at $135 each, aiming for one of the largest public offerings.

SpaceX, led by Elon Musk, is targeting a $75 billion initial public offering (IPO) by selling 555.6 million shares at $135 per share. This move is unusual as the company has set a fixed share price before the typical investor roadshow. The IPO filing...

Market News
Bullish
2 hours ago
Statkraft and Elkem sign 7-year power deal securing electricity for Bjølvefossen plant until 2037

Statkraft and Elkem sign 7-year power deal securing electricity for Bjølvefossen plant until 2037

Statkraft and Elkem ASA have agreed on a seven-year power purchase agreement from 2031 to 2037, covering 1,534 GWh to supply Elkem’s Bjølvefossen plant in Norway. This deal ensures competitive and predictable electricity, supporting local jobs and su...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App